Lovastatin

• UNSPSC Description:

  Lovastatin is a cell-permeable HMG-CoA reductase inhibitor used to lower cholesterol.

• Target Antigen:

  Autophagy; Ferroptosis; HMG-CoA Reductase (HMGCR)

• Type:

  Natural Products

• Related Pathways:

  Apoptosis;Autophagy;Metabolic Enzyme/Protease

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Cardiovascular Disease; Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Lovastatin.html

• Purity:

  99.89

• Solubility:

  DMSO : ≥ 100 mg/mL

• Smiles:

  O=C([C@@H](C)CC)O[C@@H]1[C@@]([C@H]2CC[C@@H](OC3=O)C[C@H](C3)O)([H])C(C=C[C@@H]2C)=C[C@H](C)C1

• Molecular Weight:

  404.54

• References & Citations:

  [1]Alberts AW, et al. Discovery, biochemistry and biology of lovastatin. Am J Cardiol. 1988 Nov 11;62(15):10J-15J.|[2]Kah J, et al. Selective induction of apoptosis by HMG-CoA reductase inhibitors in hepatoma cells and dependence on p53 expression. Oncol Rep. 2012 Sep;28(3):1077-83.|[3]Frishman WH, et al. Lovastatin: an HMG-CoA reductase inhibitor for lowering cholesterol. Med Clin North Am. 1989 Mar;73(2):437-48.|[4]Tobert JA, et al. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov. 2003 Jul;2(7):517-26.|[5]Ifergan I, et al. Statins reduce human blood-brain barrier permeability and restrict leukocyte migration: relevance to multiple sclerosis. Ann Neurol. 2006 Jul;60(1):45-55.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  Launched

• CAS Number:

  75330-75-5